Genetic Analysis: Record sales, first positive EBITDA, and a key pharma partnership drive future growth

About this update from Genetic Analysis As

Record Q4 sales and first positive EBITDA mark a milestone, driven by core product growth and cost reductions. Strategic partnership with Ferring Pharmaceuticals and new product launches position the company for future expansion. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genetic Analysis As